Illumina, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$341Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
315clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Oncology Testing $94K associated (2023-2025)
- Infectious Disease $33K associated (2023-2025)
- Reproductive Health $30K associated (2023-2025)
- Genetic Disease Testing $24K associated (2023-2025)
- Genetic Disease Research $5,727 associated (2023-2025)
- Oncology Testing/Genetic Disease Testing $1,529 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Eric Topol | La Jolla, CA | Cardiovascular Disease | $48,075.32 |
| Thomas Stricker | Franklin, TN | Anatomic Pathology | $9,527.12 |
| Neal Shore | Myrtle Beach, SC | Urology | $9,177.93 |
| Donald Basel | Milwaukee, WI | Clinical Genetics (M.D.) | $8,400.00 |
| Carlo Bifulco | New Haven, CT | Anatomic Pathology | $8,089.81 |
| Mark Ewalt | New York, NY | Molecular Genetic Pathology (Pathology) | $7,962.36 |
| James Solomon | New York, NY | Molecular Genetic Pathology (Pathology) | $6,784.88 |
| Eric Duncavage | Saint Louis, MO | Anatomic Pathology & Clinical Pathology | $6,331.04 |
| Nikoletta Sidiropoulos | Burlington, VT | Molecular Genetic Pathology (Medical Genetics) | $6,236.78 |
| Lucio Gordan | Gainesville, FL | Medical Oncology | $5,876.49 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.